Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.30B | 6.07B | 5.88B | 5.69B | 5.52B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.30B | 6.07B | 5.88B | 5.69B | 5.52B |
| Cost of Revenue | 1.40B | 1.33B | 1.28B | 1.20B | 1.13B |
| Gross Profit | 4.91B | 4.73B | 4.60B | 4.48B | 4.39B |
| SG&A Expenses | 2.14B | 2.08B | 1.97B | 1.88B | 1.83B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -62.30M | -67.20M | -75.60M | -40.70M | -19.40M |
| Total Operating Expenses | 4.56B | 4.43B | 4.26B | 4.10B | 3.99B |
| Operating Income | 1.74B | 1.64B | 1.62B | 1.59B | 1.53B |
| Income Before Tax | 1.30B | 1.27B | 1.57B | 1.63B | 1.61B |
| Income Tax Expenses | 224.90M | 216.90M | 235.80M | 220.40M | 176.10M |
| Earnings from Continuing Operations | 1.07K | 1.06K | 1.34K | 1.41K | 1.43K |
| Earnings from Discontinued Operations | 20.60M | 13.40M | 25.70M | 2.74B | 2.74B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.50M | 4.10M | 5.40M | 6.00M | 5.60M |
| Net Income | 1.10B | 1.07B | 1.37B | 4.15B | 4.18B |
| EBIT | 1.74B | 1.64B | 1.62B | 1.59B | 1.53B |
| EBITDA | 1.90B | 1.79B | 1.78B | 1.73B | 1.67B |
| EPS Basic | 1.88 | 1.83 | 2.33 | 6.97 | 7.01 |
| Normalized Basic EPS | 2.06 | 1.87 | 1.77 | 1.76 | 1.74 |
| EPS Diluted | 1.87 | 1.82 | 2.32 | 6.97 | 7.01 |
| Normalized Diluted EPS | 2.05 | 1.87 | 1.76 | 1.76 | 1.74 |
| Average Basic Shares Outstanding | 2.33B | 2.34B | 2.35B | 2.36B | 2.38B |
| Average Diluted Shares Outstanding | 2.34B | 2.34B | 2.35B | 2.36B | 2.38B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |